Acurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on Wednesday

Acurx Pharmaceuticals (NASDAQ:ACXP) will be posting its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.23) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period in the prior year, the company posted ($0.28) earnings per share. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

NASDAQ ACXP opened at $1.84 on Tuesday. The business’s fifty day moving average is $1.98 and its 200-day moving average is $2.15. The stock has a market capitalization of $29.90 million, a price-to-earnings ratio of -1.59 and a beta of -1.73. Acurx Pharmaceuticals has a one year low of $1.52 and a one year high of $5.28.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Acurx Pharmaceuticals in a research report on Monday, August 12th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.